Geoffrey S. Baird

About

Dr. Geoffrey S. Baird is a Professor and Chair in the Department of Laboratory Medicine & Pathology at UW Medicine, University of Washington. His clinical and research interests include lab test utilization management, proteomics, tissue analysis, general laboratory medicine, pathology, and the pathophysiology of organ systems. He is engaged in developing novel methods for clinical laboratory tests, with particular focus on technologies such as the Luminex Platform for multiplex immunoassays and the use of oligonucleotide aptamers for tissue diagnostics. Dr. Baird has established a long-term collaborative project with Ventana Medical Systems to study the formalin fixation process, aiming to monitor and optimize tissue preservation for molecular and proteomic assays. His educational background includes an MD and PhD from the University of California, San Diego, a fellowship in Immunohistochemistry at Phenopath Laboratories, and a BS in Chemistry from Stanford University.

Research topics

• Computer Science
• Medicine
• Biology
• Genetics
• Virology
• Political Science
• Evolutionary biology
• Cell biology
• Telecommunications
• Medical education

Selected publications

• Cryptic transmission of SARS-CoV-2 in Washington state

  Science · 2020 · 323 citations

  After its emergence in Wuhan, China, in late November or early December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus rapidly spread globally. Genome sequencing of SARS-CoV-2 allows the reconstruction of its transmission history, although this is contingent on sampling. We analyzed 453 SARS-CoV-2 genomes collected between 20 February and 15 March 2020 from infected patients in Washington state in the United States. We find that most SARS-CoV-2 infections sampled du…

  DOI

• Cryptic transmission of SARS-CoV-2 in Washington State

  medRxiv (Cold Spring Harbor Laboratory) · 2020 · 86 citations

  Following its emergence in Wuhan, China, in late November or early December 2019, the SARS-CoV-2 virus has rapidly spread throughout the world. On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic. Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections. Here, we analyze 346 SARS-CoV-2 genomes from samples collected between 20 February and 15 March 2020 from infected patients in…

  DOI

• The CRESS checklist for reporting stability studies: on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group for the Preanalytical Phase (WG-PRE)

  Clinical Chemistry and Laboratory Medicine (CCLM) · 2020 · 77 citations

  To ensure that clinical laboratories produce results that are both accurate and of clinical utility it is essential that only samples of adequate quality are analysed. Although various studies and databases assessing the stability of analytes in different settings do exist, guidance on how to perform and report stability studies is lacking. This results in studies that often do not report essential information, thus compromising transferability of the data. The aim of this manuscript is to descr…

  DOI

• Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues

  Clinical Chemistry · 2021-03-10 · 47 citations

  articleOpen access

  BACKGROUND: Conventional HER2-targeting therapies improve outcomes for patients with HER2-positive breast cancer (BC), defined as tumors showing HER2 protein overexpression by immunohistochemistry and/or ERBB2 gene amplification determined by in situ hybridization (ISH). Emerging HER2-targeting compounds show benefit in some patients with neither HER2 protein overexpression nor ERBB2 gene amplification, creating a need for new assays to select HER2-low tumors for treatment with these compounds.…

  PublisherOA PDFDOI

• Recommendation for the design of stability studies on clinical specimens

  Clinical Chemistry and Laboratory Medicine (CCLM) · 2023-04-06 · 44 citations

  articleOpen access

  OBJECTIVES: Knowledge of the stability of analytes in clinical specimens is a prerequisite for proper transport and preservation of samples to avoid laboratory errors. The new version of ISO 15189:2022 and the European directive 2017/746 increase the requirements on this topic for manufacturers and laboratories. Within the project to generate a stability database of European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Working Group Preanalytical Phase (WG-PRE), the need to st…

  PublisherOA PDFDOI

Frequent coauthors

• Roger Y. Tsien

  Howard Hughes Medical Institute

  24 shared

• Andrew N. Hoofnagle

  University of Washington

  17 shared

• Anthony M. Avellino

  Banner - University Medical Center Tucson

  16 shared

• Jason J. Chang

  16 shared

• Shu‐Ching Hu

  16 shared

• Thomas J. Montine

  Stanford University

  16 shared

• Ana-Maria Šimundić

  15 shared

• Janne Cadamuro

  Paracelsus Medical University

  15 shared

Education

• M.D.

  University of Washington

• Ph.D.

  University of Washington

Similar researchers at University of Washington

• Charles E. Alpersh-112
• William Altemeierh-66
• Cynthia A. Derdeynh-55